or
Remember me
Back
BNHLF has a niche drug in their hands with lots of potential.
The shortcomings of the Phase 3 study are not insurmountable.
This stock is significantly undervalued, especially after the ADCOM announcement.
Receive investor kits and email updates from Stockhouse and directly from these companies.